ImCheck Therapeutics SAS

The pace of initial public offerings in the US predictably slowed during the summer, although whether the slowdown was caused by financial market conditions or vacation schedules remains to be seen. E

The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just

Venture capital investment in biopharmaceutical companies has been remarkable throughout 2020, both in terms of individual company fundraisings and new VC funds, including two funds totaling $755m tha

Freshly funded via a $53m series B financing round, France-based ImCheck Therapeutics SAS can now enter the clinic with its lead monoclonal antibody and test its potential to activate gamma delta T-